Table 5 Tumor characteristics in cases with total cases and rare alleles

Age

   Mean

63.9 (42-78)

64.1 (46-80)

64.3 (40-83)

67.9 (50-88)

64.7 (55-81)

T-stage

   T1

0 (0.0%)

0 (0.0%)

130 (41.0%)

42 (13.2%)

0 (0.0%)

   T2

116 (62.4%)

52 (63.4%)

183 (57.7%)

139 (43.8%)

3 (42.9%)

   T3

68 (36.6%)

29 (35.4%)

4 (1.3%)

95 (30.0%)

1 (14.3%)

   T4

2 (1.1%)

1 (1.2%)

0 (0.0%)

41 (12.9%)

3 (42.9%)

N-stage

   N0

182 (97.8%)

45 (91.8%)

291 (91.8%)

265 (85.8%)

3 (42.9%)

   N1

4 (2.2%)

4 (8.2%)

26 (8.2%)

44 (14.2%)

4 (57.1%)

M-stage

   M0

158 (84.9%)

45 (91.8%)

280 (88.3%)

247 (75.5%)

3 (37.5%)

   M1

28 (15.1%)

4 (8.2%)

37 (11.7%)

80 (24.5%)

5 (62.5%)

Gleason score

   2-6

34 (18.3%)

22 (31.9%)

126 (39.8%)

71 (23.5%)

1 (12.5%)

   7

108 (58.0%)

33 (47.8%)

98 (30.9%)

95 (31.5%)

1 (12.5%)

   8-10

44 (23.7%)

14 (20.3%)

93 (29.3%)

136 (45.0%)

6 (75.0%)

PSA (ng/ml)

   <10

110 (59.1%)

41 (49.4%)

142 (44.8%)

29 (34.1%)

0 (0.0%)

   10-20

57 (30.7%)

21 (25.3%)

102 (32.2%)

8 (9.4%)

0 (0.0%)

   >20

19 (10.2%)

21 (25.3%)

73 (23.0%)

48 (56.5%)

3 (100%)

Jewett-Whitmore system

   A

35 (10.7%)

0 (0.0%)

   B

126 (38.4%)

1 (12.5%)

   C

67 (20.4%)

1 (12.5%)

   D

100 (30.5%)

6 (75.0%)

Tumor grade

   Well

25 (7.9%)

9 (3.0%)

0 (0.0%)

   Moderate

101 (31.9%)

62 (20.5%)

1 (12.5%)

   Poor

191 (60.3%)

231 (76.5%)

7 (87.5%)